# Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder

> **NCT00437099** · PHASE4 · UNKNOWN · sponsor: **Hospital Universitari Vall d'Hebron Research Institute** · enrollment: 102 (estimated)

## Conditions studied

- Borderline Personality Disorder.

## Interventions

- **DRUG:** Omacor®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00437099
- **Lead sponsor:** Hospital Universitari Vall d'Hebron Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-02
- **Primary completion:** 2011-02
- **Final completion:** 2011-09
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2010-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00437099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00437099, "Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT00437099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*